Table of Contents Table of Contents
Previous Page  44 / 88 Next Page
Information
Show Menu
Previous Page 44 / 88 Next Page
Page Background

42

NCCN Guidelines for Patients

®

:

Brain Cancer – Gliomas, Version 1.2016

Guide 9 continued

Post-surgery treatment

Your performance status: KPS ≥60

Your age

MGMT

promotor

status

What are the options?

≤70 years

ª

Methylated

ª

• Temozolomide during and after fractionated EBRT

◦◦ With alternating electric field therapy for upper brain tumors

ª

Unmethylated

or unknown

ª

• Temozolomide during and after fractionated EBRT

◦◦ With alternating electric field therapy for upper brain tumors

ª

• Fractionated EBRT

≥71 years

ª

Methylated

ª

• Hypofractionated EBRT

ª

• Temozolomide during and after hypofractionated EBRT

ª

• Temozolomide during and after fractionated EBRT

◦◦ With alternating electric field therapy for upper brain tumors

ª

• Temozolomide

ª

Unmethylated

or unknown

ª

• Hypofractionated EBRT

ª

• Temozolomide during and after fractionated EBRT

◦◦ With alternating electric field therapy for upper brain tumors

Your performance status: KPS ≤59

What are the options?

• Fractionated EBRT if 70 years of age or younger

• Hypofractionated EBRT

• Temozolomide if methylated MGMT promotor regions

• Best supportive care

3

Astrocytomas

Glioblastomas and gliosarcomas